drugset / Trial / NCT00514163
GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to compare tumor response rate of the test arm(gemcitabine+S-1) with the control arm(gemcitabine alone) in patients with unresectable pancreatic cancer
Timeline
- Start
- 2007-06
- Primary completion
- 2010-08
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | S-1 | Small molecule | — | Oral |